Table 1.

Baseline characteristics and medication use of study population (not imputed data), separated by occurrence of joint damage progression between 0 and 3 years. Values are mean (SD), % (n), or median (IQR).

CharacteristicsJoint Damage ProgressionNo Joint Damage Progressionp
nMean/Med/%nMean/Med/%
Age, yrs17554 (14)25057 (14)0.029
Female17559% (104)25066% (165)0.167
Anti-CCP–positive15882% (129)21353% (112)< 0.001
RF–positive17587% (153)24666% (163)< 0.001
SE present16475% (123)18868% (128)0.153
Smoking, ever13172% (94)17667% (118)0.377
DAS281705.5 (1.3)2414.9 (1.4)< 0.001
ESR, mm/h16840 (21–59)23821 (9–38)< 0.001
CRP, mg/l11822 (7–52)2063 (0–23)< 0.001
SJC2817311 (7–16)24410 (6–14)0.017
SJC4414215 (10–22)15313 (9–19)0.041
TJC281737 (4–13)2446 (2–12)0.070
TJC5314213 (6–19)15312 (5–19)0.269
VAS pain, 0–10015747 (28–60)22847 (31–64)0.241
Erosions at BL17562% (108)25032% (80)< 0.001
Ratingen score1752 (0–4)2500 (0–1)< 0.001
DMARD1692500.253
  Combination21% (37)20% (51)
  Monotherapy75% (132)72% (181)
Oral prednisone17561% (107)25061% (152)0.943
  • Joint damage progression was defined as ≥ 5 Ratingen points. Treatment with synthetic DMARD and oral prednisone was evaluated between 0 and 36 months. Statistic tests used were unpaired Student t test, chi-square test, and Mann-Whitney U test, as appropriate. IQR: interquartile range; anti-CCP: anticyclic citrullinated peptide antibodies; RF: rheumatoid factor; SE: shared epitope; DAS28: Disease Activity Score at 28 joints; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; SJC28: swollen joint count at 28 joints; TJC28: tender joint count at 28 joints; VAS: visual analog scale; BL: baseline; DMARD: disease-modifying antirheumatic drug.